65971-74-6

Usage

Uses

Used in Pharmaceutical Research:
Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)is used as a building block in pharmaceutical research for the synthesis of various biologically active compounds and pharmaceuticals. Its unique structure and properties make it a valuable component in the development of potential drug candidates.
Used in Organic Synthesis:
Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)is used as a reagent in organic synthesis, where its bromine atom and hydroxyimino group can be utilized in various chemical reactions to produce a range of compounds.
Used in Antimicrobial Applications:
Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)is used for its potential antimicrobial properties, making it a candidate for the development of new antimicrobial agents to combat resistant bacteria.
Used in Antifungal Applications:
Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)is also used for its potential antifungal properties, which can be harnessed to develop new antifungal drugs to treat fungal infections.

Upstream product

• 302-17-0 chloral hydrate 
• 591-19-5 m-Bromoaniline 
• 75-87-6 chloral 

Downstream Products

• 99365-40-9 6-bromo-2,3-dihydro-1H-indole-2-one 
• 20780-72-7 4-bromoisatin 
• 6326-79-0 6-bromoisatin 
• 884855-67-8 4-bromo-1-methylindoline-2,3-dione 

Relevant academic research and scientific papers

Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors

Saccharomonosporine A was recently reported as a natural anti-cancer agent working through inhibition of a Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase. Structural bioisosteres of this natural product were synthesized and t

Preparation method and application of compounds BIA-01 and BIA-02 with CDC25B inhibitory activity

The invention relates to the field of medicine synthesis. The invention aims to solve the problems of insufficient drug targeting treatment precision, insufficient substituent group activity and poorbinding capacity with an acting part in the prior art. The invention discloses a preparation method and an application of compounds BIA-01 and BIA-02 with CDC25B inhibitory activity. The preparation method comprises the following steps: i, synthesis of 1a-(E)-N-(3-bromophenyl)-2-(oximido)acetamide; ii, synthesis of 2a-6-bromoindoline-2,3-diketone; iii, synthesis of a 3a,3b-N-chloroacetyl aniline derivative; iiii, synthesis of BIA-01, BIA-02-6-bromo-2,3-dioxoindoline-1-N-substituted phenyl acetamide. The compound BIA-01 and the compound BIA-02 which are high in antitumor activity and low in side effect are prepared, and the compounds have a high inhibition effect on tumors.

Indolone compound as well as preparation method and application thereof

The invention relates to an indolone compound, which is 1-(4-chlorobenzyl)-3-(hydroxyimino)-4-(4-(trifluoromethyl)phenyl)-dihydroindol-2-one. The indolone compound can be used for effectively inhibiting the activity of an hTERT gene promoter; shown by a s

Inhibitor of the human telomerase reverse trancriptase (hTERT) gene promoter induces cell apoptosis via a mitochondrial-dependent pathway

Telomerase is aberrantly expressed in many cancers and plays an important role in the development of cellular immortality and oncogenesis, which makes it a potential cancer therapeutic target for drug discovery. Here, we constructed a firefly luciferase r

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.

Isatin N,N′-Cyclic Azomethine Imine 1,3-Dipole and Abnormal [3 + 2]-Cycloaddition with Maleimide in the Presence of 1,4-Diazabicyclo[2.2.2]octane

A new isatin N,N′-cyclic azomethine imine synthon was devised, and an unexpected abnormal [3 + 2]-cycloaddition with maleimide catalyzed by 1,4-diazabicyclo[2.2.2]octane (DABCO) has been disclosed. A variety of tricyclic spiropyrrolidine oxindoles bearing a dinitrogen heterocycle and succinimide scaffold were obtained in excellent yields (up to 96%) and diastereoselectivities (up to 97:3) under mild conditions.

Methylisoindigo and its bromo-derivatives are selective tyrosine kinase inhibitors, repressing cellular stat3 activity, and target CD133+ cancer stem cells in PDAC

Indirubin is an active component of the herbal ingredient 'Danggui Longhui wan', which was used for the treatment of inflammation and chronic myeloid leukemia in China. The recent study showed its derivative methylisoindigo (also known as meisoindigo) preferentially targeting cancer stem cells (CSCs) in interference with AMPK and LKB1, the cellular metabolic sensors. In this study, we screened the effect of meisoindigo on a panel of 300 protein kinases and found that it selectively inhibited Stat3-associated tyrosine kinases and further confirmed its activity in cell based assays. To gain a deeper insight into the structure-activity relationship we produced 7 bromo-derivatives exhausting the accessible positions on the bisindole backbone except for in the 4-position due to the space limitation. We compared their anti-proliferative effects on tumor cells. We found that 6-bromomeisoindigo showed improved toxicity in company with increased Stat3 inhibition. Moreover, we detected that 6-bromomeisoindigo induced apoptosis of 95% of CD133+ pancreatic cancer cells. Considering that CD133 is a common marker highly expressed in a range of CSCs, our results imply the potential application of 6-bromomeisoindigo for the treatment of CSCs in different types of cancers.

A 3 - arylhydrazine substituted indole derivative and its preparation method and application

The invention relates to a 3-aryl hydrazine substituted indolone derivative, as well as a preparation method and application thereof. According to the derivative described in the Specification, R is hydrogen, 4-methyl, 4-chloro, 3,4-dichloro, 3,5-dichloro

A cinchona alkaloid catalyzed enantioselective sulfa-Michael/aldol cascade reaction of isoindigos: Construction of chiral bispirooxindole tetrahydrothiophenes with vicinal quaternary spirocenters

A cinchona alkaloid catalyzed diastereoselective and enantioselective sulfa-Michael/aldol cascade reaction between 1,4-dithiane-2,5-diol and isoindigos has been successfully developed to afford the highly congested bispirooxindole tetrahydrothiophenes with vicinal quaternary spirocenters in high yields (up to 91%), excellent diastereoselectivities (up to >20 : 1 dr), and good enantioselectivities (up to 98% ee). Some synthetic transformations of the reaction products were also studied.

6-bromo-2,3-dioxoindolin phenylacetamide derivatives: Synthesis, potent CDC25B, PTP1B inhibitors and anticancer activity

A series of 6-bromo-2,3-dioxoindolin phenylacetamide derivatives was synthesized and evaluated for inhibitory activity against CDC25B and PTP1B. Most of the synthesized compounds showed potential inhibitory activities for CDC25B and PTP1B with compound 12 being the most potent (IC50=3.87μmol/L and 2.98 μmol/L, respectively). Compound 12 also exhibited higher cytotoxic activity against three cancer cell lines (HeLa, A549 and HCT116). In addition, compound 12 delayed the potent tumor inhibitory activity in a colo205 xenograft model in vivo.